Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 178

1.

A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).

Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC.

Nephron. 2015 Jun 12. [Epub ahead of print]

PMID:
26087670
2.

Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy.

Thompson A, Cattran DC, Blank M, Nachman PH.

J Am Soc Nephrol. 2015 Jun 15. pii: ASN.2015010091. [Epub ahead of print]

PMID:
26078365
3.

The authors reply:.

Troyanov S, Cattran D, Coppo R.

Kidney Int. 2015 Mar;87(3):662-3. doi: 10.1038/ki.2014.402. No abstract available.

PMID:
25723639
4.

Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study.

Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts IS, Cattran D, Coppo R; on behalf of the VALIGA study of the ERA-EDTA Immunonephrology Working Group.

J Am Soc Nephrol. 2015 Feb 12. pii: ASN.2014070697. [Epub ahead of print]

PMID:
25677392
5.

The (99m)Tc-DTPA urinary clearance method may be preferable to the plasma disappearance method for assessing glomerular filtration rate in diabetic nephropathy.

Huang SH, Eliasziw M, Spence JD, Filler G, Vezina WC, Churchill DN, Cattran DC, Richardson B, House AA.

Nephron Clin Pract. 2014;128(3-4):367-72. doi: 10.1159/000368901. Epub 2015 Jan 8.

PMID:
25571980
6.

The authors reply.

Dhaun N, Bellamy CO, Cattran DC, Kluth DC.

Kidney Int. 2014 Dec;86(6):1269. doi: 10.1038/ki.2014.278. No abstract available.

PMID:
25427088
7.

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.

Spinale JM, Mariani LH, Kapoor S, Zhang J, Weyant R, Song PX, Wong HN, Troost JP, Gadegbeku CA, Gipson DS, Kretzler M, Nihalani D, Holzman LB; Nephrotic Syndrome Study Network.

Kidney Int. 2015 Mar;87(3):564-74. doi: 10.1038/ki.2014.346. Epub 2014 Oct 29.

PMID:
25354239
8.

The molecular phenotype of endocapillary proliferation: novel therapeutic targets for IgA nephropathy.

Hodgin JB, Berthier CC, John R, Grone E, Porubsky S, Gröne HJ, Herzenberg AM, Scholey JW, Hladunewich M, Cattran DC, Kretzler M, Reich HN.

PLoS One. 2014 Aug 18;9(8):e103413. doi: 10.1371/journal.pone.0103413. eCollection 2014.

9.

Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis.

Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T; Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).

Am J Kidney Dis. 2014 Jul;64(1):74-85. doi: 10.1053/j.ajkd.2014.02.020. Epub 2014 Apr 29.

10.

A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy.

Hladunewich MA, Cattran D, Beck LH, Odutayo A, Sethi S, Ayalon R, Leung N, Reich H, Fervenza FC.

Nephrol Dial Transplant. 2014 Aug;29(8):1570-7. doi: 10.1093/ndt/gfu069. Epub 2014 Apr 8.

11.

Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments.

Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, Roberts IS, Morando L, Camilla R, Tesar V, Lunberg S, Gesualdo L, Emma F, Rollino C, Amore A, Praga M, Feriozzi S, Segoloni G, Pani A, Cancarini G, Durlik M, Moggia E, Mazzucco G, Giannakakis C, Honsova E, Sundelin BB, Di Palma AM, Ferrario F, Gutierrez E, Asunis AM, Barratt J, Tardanico R, Perkowska-Ptasinska A; VALIGA study of the ERA-EDTA Immunonephrology Working Group.

Kidney Int. 2014 Oct;86(4):828-36. doi: 10.1038/ki.2014.63. Epub 2014 Apr 2.

12.

Utility of renal biopsy in the clinical management of renal disease.

Dhaun N, Bellamy CO, Cattran DC, Kluth DC.

Kidney Int. 2014 May;85(5):1039-48. doi: 10.1038/ki.2013.512. Epub 2014 Jan 8. Review. Erratum in: Kidney Int. 2014 Dec;86(6):1268.

PMID:
24402095
13.

Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy.

Lee T, Biddle AK, Lionaki S, Derebail VK, Barbour SJ, Tannous S, Hladunewich MA, Hu Y, Poulton CJ, Mahoney SL, Charles Jennette J, Hogan SL, Falk RJ, Cattran DC, Reich HN, Nachman PH.

Kidney Int. 2014 Jun;85(6):1412-20. doi: 10.1038/ki.2013.476. Epub 2013 Dec 11.

14.

ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption.

Ashraf S, Gee HY, Woerner S, Xie LX, Vega-Warner V, Lovric S, Fang H, Song X, Cattran DC, Avila-Casado C, Paterson AD, Nitschké P, Bole-Feysot C, Cochat P, Esteve-Rudd J, Haberberger B, Allen SJ, Zhou W, Airik R, Otto EA, Barua M, Al-Hamed MH, Kari JA, Evans J, Bierzynska A, Saleem MA, Böckenhauer D, Kleta R, El Desoky S, Hacihamdioglu DO, Gok F, Washburn J, Wiggins RC, Choi M, Lifton RP, Levy S, Han Z, Salviati L, Prokisch H, Williams DS, Pollak M, Clarke CF, Pei Y, Antignac C, Hildebrandt F.

J Clin Invest. 2013 Dec;123(12):5179-89. doi: 10.1172/JCI69000. Epub 2013 Nov 25.

15.

Glomerular diseases: FSGS.

Bose B, Cattran D; Toronto Glomerulonephritis Registry.

Clin J Am Soc Nephrol. 2014 Mar;9(3):626-32. doi: 10.2215/CJN.05810513. Epub 2013 Aug 29. Review.

16.

Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis.

Lv J, Shi S, Xu D, Zhang H, Troyanov S, Cattran DC, Wang H.

Am J Kidney Dis. 2013 Nov;62(5):891-9. doi: 10.1053/j.ajkd.2013.04.021. Epub 2013 Jun 29. Review.

PMID:
23820066
17.

Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease.

Barbour SJ, Cattran DC, Kim SJ, Levin A, Wald R, Hladunewich MA, Reich HN.

Kidney Int. 2013 Nov;84(5):1017-24. doi: 10.1038/ki.2013.210. Epub 2013 Jun 5.

PMID:
23739233
18.

Short-term complications of membranous nephropathy.

Barbour S, Reich H, Cattran D.

Contrib Nephrol. 2013;181:143-51. doi: 10.1159/000349976. Epub 2013 May 8. Review.

PMID:
23689576
19.

The authors reply.

Radhakrishnan J, Cattran D.

Kidney Int. 2013 May;83(5):969. doi: 10.1038/ki.2013.22. No abstract available.

PMID:
23633057
20.

A pilot study of reduced dose cyclosporine and corticosteroids to reduce new onset diabetes mellitus and acute rejection in kidney transplant recipients.

Cole EH, Prasad GV, Cardella CJ, Kim JS, Tinckam KJ, Cattran DC, Schiff JR, Landsberg DN, Zaltzman JS, Gill JS.

Transplant Res. 2013 Jan 12;2(1):1. doi: 10.1186/2047-1440-2-1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk